{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-324865","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2026-07-30T11:05:07+00:00","discovered_at":"2026-07-30T11:10:00.288625+00:00","generated_at":"2026-07-30T11:10:45.999103+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Phathom Q2 revenue $74.3M (+88% YoY); net loss narrows to $17.6M; initiates Phase 3 NERD trial","bullets":["Record Q2 net revenue $74.3M, up 88% YoY and 27% QoQ; operating expenses $63.1M, down 33% YoY.","Net loss $17.6M vs $75.8M in Q2 2025; non-GAAP adjusted net loss nearly zero at $0.1M.","~325,000 VOQUEZNA prescriptions in Q2 (+88% YoY); ~1.7M total to date.","Initiating Phase 3 trial for as-needed VOQUEZNA in NERD; first enrollment expected Q4 2026.","Completed enrollment in Phase 2 EoE trial; topline results expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-324865","json":"https://secwatch.observer/filing/0001193125-26-324865.json","markdown":"https://secwatch.observer/filing/0001193125-26-324865.md","text":"https://secwatch.observer/filing/0001193125-26-324865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/0001193125-26-324865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/d114879d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T11:10:45.999103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}